Predicting therapeutic and aggravating drugs for hepatocellular carcinoma based on tissue-specific pathways
Motivation: Hepatocellular carcinoma (HCC) is a significant health problem worldwide and annual number of cases are nearly more than 700,000. However,there are few safe and effective thera-peutic options for HCC patients.Here, we propose a new approach for predicting therapeutic and aggravating drugs for HCCbased ontissue-specificpathways, which considersnot onlyliver tis-sueand functional informationof pathways, but also the changes of single gene in pathways. Results: Firstly, we map genes related to HCC to the liver-specific protein interaction network and get anextended tissue-specific gene set of HCC. Then, based on the extended gene set, 12 en-riched KEGGfunctional pathways are extracted.Using Kolmogorov-Smirnov statistic, we calculate the therapeutic scores of drugs based on the 12 tissue-specific pathways. Finally, after filtering by Comparative Toxicogenomics Database (CTD) benchmark,we get 3 therapeutic drugs and 3 ag-gravating drugs for HCC. Furthermore, we validate the6potentially related drugs of HCC by analyz-ingtheiroverlaps with drug indications reported in PubMed literatures, and also making CMapprofile similarity analysis and KEGG enrichment analysis based on their targets. All analysis results sug-gest thatour approach is effective and accurate for discovering novel therapeutic options for HCC and it can be easily extended to other diseases.More importantly, our method can clearly distin-guish therapeutic and aggravating drugsforHCC, which also can be used to indicateunmarked drug-disease associations in CTD as positive or negative.
Code (0)
등록된 구현이 없습니다.
Similar Papers 제목 키워드 기반
Discovery of new drug therapeutic indications from gene mutation information for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is a leading cause of cancer-related death worldwide. However, cure is not possible with currently used therapies, and there is not so much a…
Hepatocellular Carcinoma Intra-arterial Treatment Response Prediction for Improved Therapeutic Decision-Making
This work proposes a pipeline to predict treatment response to intra-arterial therapy of patients with Hepatocellular Carcinoma (HCC) for improved therapeutic decision-making. Our graph neural network model seamlessly co…
Decision MakingGraph Neural NetworkIdentifying downregulated hub genes and key pathways in HBV-related hepatocellular carcinoma using systems biology approach
Chronic Hepatitis B (CHB) is an independent risk factor for hepatocellular carcinoma (HCC) initiation without cirrhosis occurrence. Apart from the favorable effects of some antiviral drugs following tumor resection on th…
DiagnosticTumor-associated CD19$^+$ macrophages induce immunosuppressive microenvironment in hepatocellular carcinoma
Tumor-associated macrophages are a key component that contributes to the immunosuppressive microenvironment in human cancers. However, therapeutic targeting of macrophages has been a challenge in clinic due to the limite…
Leveraging weak complementary labels to improve semantic segmentation of hepatocellular carcinoma and cholangiocarcinoma in H&E-stained slides
In this paper, we present a deep learning segmentation approach to classify and quantify the two most prevalent primary liver cancers - hepatocellular carcinoma and intrahepatic cholangiocarcinoma - from hematoxylin and …
DiagnosticSegmentationSemantic Segmentationwhole slide images